ARTICLE | Clinical News
VGX-100: Phase I started
January 16, 2012 8:00 AM UTC
Circadian began a dose-escalation, U.S. Phase I trial to evaluate VGX-100 as monotherapy and in combination with anti-angiogenic agents in patients with advanced solid tumors who have no other standar...